Majority of ulcerative colitis patients not achieving clinical, endoscopic remission — 5 key notes

A study, published in the Journal of Gastroenterology and Hepatology, examined how many ulcerative colitis patients reached both clinical and endoscopic remission through a "Treat to Target" approach.

Robert Bryant, PhD, of Australia-based University of Adelaide, and colleagues examined 246 ulcerative colitis patients treated with the "Treat to Target" approach in a multicenter, retrospective, cross-sectional review of patients. Researchers recorded clinical and objective assessments of disease activity.

Here's what they found:

1. Sixty-one percent of ulcerative colitis patients were in clinical readmission.

2. Thirty-five percent were in clinical and endoscopic remission.

3. Sixteen percent were in concordant clinical, endoscopic and histological remission.

4. Clinician-related factors affected outcomes at a higher rate than disease-related factors.

5. Physicians used C-reactive protein more than endoscopy as a biomarker of disease activity.

Researchers concluded, "Most patients with UC do not achieve composite clinical and endoscopic remission in ‘real-world' practice. Clinician uptake of proposed ‘Treat to Target' guidelines is a challenge to their implementation."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast